课题基金 / 基金详情

CD47/IAP Modulation of Immune Cell Functions

CD47/IAP Modulation of Immune Cell Functions
CD47/IAP 调节免疫细胞功能
批准号:
6917763
负责人:
WILLIAM A FRAZIER
金额:
$5.74万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
1998
资助国家:
美国
项目状态:
已结题
起止时间:
1998-05-01 至 2007-04-30

项目摘要

项目成果

WILLIAM A FRAZIER的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): As a result of work during the first cycle of this grant, we realize that CD47 or integrin-associated protein can modulate the function of a number of vascular integrins through its direct activation of heterotrimeric Gi. Much less is known about CD47 function in the immune system. We have found that CD47 and its counter receptor SIRPalpha constitute a novel recognition of self system that prevents phagocytosis of CD47-bearing circulating cells. Failure of this system leads to autoimmune syndromes. All ligands of CD47 (thrombospondin, monoclonal antibodies and SIRPalpha can induce a novel form of cell death in activated lymphocytes, i.e., Jurkats and anti-CD3 activated normal T cells. The mechanism involves heterotrimeric G proteins and attenuation of PKA activity leading to a loss of delta-psi-m. We find that CD47 null mice have a severe defect in IgM to IgG class switching. Here we propose to investigate the mechanisms behind these newly revealed functions of CD47 in the immune system. The aims are: 1. Determine the biological role and mechanism of the CD47-SIRPalpha inhibition of phagocytosis of circulating cells. This normally attenuates presentation of self antigens and its mechanism suggests a novel treatment for autoimmune hemolytic anemia. 2. Investigate the mechanism of CD47 mediated cell death, particularly the connection from G proteins to mitochondrial damage. 3. Use CD47 null mice to define the role of CD47 in development of immune cells, in class switching during an immune response and in autoimmunity.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Tumor-toxic CD47 mAb therapy for leukemia: a proof of concept study
  • 批准号:
    8520948
  • 项目类别:
  • 资助金额:
    $29.97万
  • 财政年份:
    2013
  • 负责人:
    WILLIAM A FRAZIER
  • 依托单位:
Development of a humanized anti-CD47 antibody for treatment of tissue ischemia.
  • 批准号:
    7669899
  • 项目类别:
  • 资助金额:
    $19.77万
  • 财政年份:
    2009
  • 负责人:
    WILLIAM A FRAZIER
  • 依托单位:
Integrin Associated Protein in a Thrombospondin Receptor
  • 批准号:
    6752865
  • 项目类别:
  • 资助金额:
    $38.25万
  • 财政年份:
    2002
  • 负责人:
    WILLIAM A FRAZIER
  • 依托单位:
Integrin Associated Protein in a Thrombospondin Receptor
  • 批准号:
    7418842
  • 项目类别:
  • 资助金额:
    $38.0万
  • 财政年份:
    2002
  • 负责人:
    WILLIAM A FRAZIER
  • 依托单位:
国内基金
海外基金
Epac1/2通过蛋白酶体调控中性粒细胞NETosis和Apoptosis在急性肺损伤中的作用研究
  • 批准号:
    LBY21H010001
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2020
  • 负责人:
    郑绪阳
  • 依托单位:
去乙酰化酶SIRT1在前体mRNA可变剪切中的作用及其生理病理效应研究
  • 批准号:
    31970691
  • 项目类别:
    面上项目
  • 资助金额:
    58.0万元
  • 批准年份:
    2019
  • 负责人:
    张胜萍
  • 依托单位:
TM9SF4调控非小细胞肺癌细胞凋亡机制研究
  • 批准号:
    31900527
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    24.0万元
  • 批准年份:
    2019
  • 负责人:
    孙磊
  • 依托单位:
基于Apoptosis/Ferroptosis双重激活效应的天然产物AlbiziabiosideA的抗肿瘤作用机制研究及其结构改造
  • 批准号:
    81703335
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    20.0万元
  • 批准年份:
    2017
  • 负责人:
    卫高菲
  • 依托单位: